|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-8-7
|
|
pubmed:abstractText |
Activation of Smad1 signaling has recently been implicated in the development of fibrosis. The goal of the present study was to gain further insights into activation of the Smad1 pathway in fibrosis in systemic sclerosis (SSc) and to determine whether this pathway is targeted by the antifibrotic drug imatinib mesylate.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CTGF protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Connective Tissue Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Immediate-Early Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Mitogen-Activated Protein Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/SMAD1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Smad1 Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2528-37
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18668566-Adult,
pubmed-meshheading:18668566-Aged,
pubmed-meshheading:18668566-Biopsy,
pubmed-meshheading:18668566-Case-Control Studies,
pubmed-meshheading:18668566-Cells, Cultured,
pubmed-meshheading:18668566-Connective Tissue Growth Factor,
pubmed-meshheading:18668566-Female,
pubmed-meshheading:18668566-Fibroblasts,
pubmed-meshheading:18668566-Humans,
pubmed-meshheading:18668566-Immediate-Early Proteins,
pubmed-meshheading:18668566-Intercellular Signaling Peptides and Proteins,
pubmed-meshheading:18668566-Male,
pubmed-meshheading:18668566-Middle Aged,
pubmed-meshheading:18668566-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:18668566-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:18668566-Piperazines,
pubmed-meshheading:18668566-Protein Kinase Inhibitors,
pubmed-meshheading:18668566-Pyrimidines,
pubmed-meshheading:18668566-Scleroderma, Systemic,
pubmed-meshheading:18668566-Signal Transduction,
pubmed-meshheading:18668566-Skin,
pubmed-meshheading:18668566-Smad1 Protein,
pubmed-meshheading:18668566-Transforming Growth Factor beta
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
|
|
pubmed:affiliation |
Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC 29425-6370, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
